How Wegovy and Mounjaro Dosing Schedules Actually Compare
Wegovy vs Mounjaro Dosage Chart: Understanding the True Cost Difference
The Wegovy vs Mounjaro dosage chart reveals significant differences in escalation schedules and pricing structures. Wegovy follows a 5-stage dose escalation over 16 weeks (0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg maintenance), whilst Mounjaro uses 4 escalation steps over 12 weeks (2.5mg, 5mg, 7.5mg, then maintenance options of 10mg or 15mg). Understanding these dosing patterns is crucial for budgeting your weight management journey. Unlike competitor pharmacies that add consultation fees, prescription charges, and administration costs at checkout, EverydayMeds provides complete price transparency from the start.
Our Wegovy vs Mounjaro dosage chart comparison shows that Wegovy's longer escalation period may suit patients preferring gradual dose increases, whilst Mounjaro's faster escalation reaches therapeutic levels sooner. Both treatments require careful medical supervision during dose escalation, with prescriber reviews ensuring safety and effectiveness. The total cost difference becomes apparent when comparing 16-week Wegovy escalation (£524.96 for all escalation doses) versus 12-week Mounjaro escalation, but hidden fees from other providers can substantially increase these base costs.
Complete Wegovy Pricing Structure: No Hidden Consultation Fees
Our transparent Wegovy vs Mounjaro dosage chart pricing shows exactly what you'll pay for each escalation phase. Wegovy pricing includes: 0.25mg starter dose £79.99, 0.5mg £94.99, 1mg £99.99, 1.7mg £139.99, and 2.4mg maintenance £209.99. These prices include everything—clinical assessment, prescriber review (GPhC #9012878), prescription issuance, and medication supply. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25, with these final prices already reflecting discount application.
Bundle options provide convenient supply management without the stress of reordering individual pens. Our Getting Started bundles include the Intro Duo (0.25mg & 0.5mg) for £169.99, and Progress Duo (0.5mg & 1mg) for £189.99. For patients preferring extended supply, our 3-pen Ultimate Stability Trio provides three months of 2.4mg maintenance for £649.99. Unlike competitors charging separate consultation fees (often £30-50 per assessment), prescription fees (£15-25), and administration charges, every EverydayMeds price represents the complete service cost.
Clinical Evidence Supporting Wegovy vs Mounjaro Dosage Chart Decisions
Understanding the Wegovy vs Mounjaro dosage chart requires reviewing clinical evidence supporting each escalation schedule. Wegovy's dosing protocol derives from the STEP clinical trial programme, where participants following the 16-week escalation achieved an average clinically studied weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The gradual dose increases in Wegovy may help minimise gastrointestinal side effects whilst building therapeutic levels.
Mounjaro's dosing evidence comes from the SURMOUNT trials, demonstrating effectiveness with its faster 12-week escalation schedule. However, direct comparison between Wegovy vs Mounjaro dosage chart outcomes requires caution, as trial designs, participant populations, and endpoints differed between studies. Both treatments showed significant weight management benefits when used alongside lifestyle interventions, but individual response varies considerably.
How Wegovy Works: GLP-1 Mechanism and Dosing Rationale
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural fullness hormone produced in your intestines. The Wegovy vs Mounjaro dosage chart reflects different approaches to achieving therapeutic GLP-1 activation—Wegovy uses pure GLP-1 receptor stimulation, whilst Mounjaro combines GLP-1 with GIP receptor activation. Wegovy's once-weekly injection via FlexTouch pen reduces appetite by acting on brain appetite centres, promoting feelings of fullness after smaller meals, and potentially reducing food cravings. The gradual dose escalation allows your body to adapt to increased GLP-1 activity whilst minimising side effects. Each dose increase in the Wegovy schedule builds upon previous therapeutic effects, with the final 2.4mg maintenance dose providing optimal appetite regulation for most patients.
Ordering Process: From Assessment to Delivery
Accessing Wegovy through our transparent pricing structure begins with a 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Your assessment undergoes prescriber review within 3 working days (or 24 hours with express service), ensuring clinical suitability for Wegovy therapy. Once approved, your medication ships via next-day delivery using cold-chain temperature-controlled packaging, maintaining the 2-8°C storage requirements throughout transit. Our GPhC-registered pharmacy (#9012878) handles all prescription processing, eliminating separate prescription fees charged by competitor services. The entire process maintains complete cost transparency—the price you see during ordering is the final amount charged, with no additional consultation fees, prescription charges, or administration costs appearing at checkout.
Storage and Practical Considerations in Wegovy vs Mounjaro Comparison
The Wegovy vs Mounjaro dosage chart comparison extends beyond dosing schedules to practical storage differences. Wegovy pens require refrigerator storage at 2-8°C before first use, but offer superior travel flexibility with 6 weeks room temperature stability (below 30°C) once removed from refrigeration. Mounjaro provides only 21 days room temperature storage, making Wegovy more suitable for extended travel or irregular schedules. Each Wegovy FlexTouch pen delivers multiple doses according to your current escalation stage, with clear dose markings and safety features preventing accidental overdosing. The dose escalation cannot be rushed—each 4-week phase is mandatory for safety and tolerability, making bundle planning essential for uninterrupted treatment. Proper injection technique and site rotation help minimise injection site reactions during the escalation period.
Why Transparent Wegovy vs Mounjaro Dosage Chart Pricing Matters for UK Patients
The UK online pharmacy market often obscures true treatment costs through hidden fees, making Wegovy vs Mounjaro dosage chart cost comparisons difficult. Many providers advertise low medication prices whilst charging separate consultation fees (£30-65), prescription processing fees (£15-35), and administrative charges that can double the advertised cost. This pricing opacity particularly impacts patients requiring multiple dose escalations, where hidden fees multiply across each prescription.
EverydayMeds eliminates this confusion by including all service components in our listed prices. When comparing Wegovy vs Mounjaro dosage chart costs, our transparent structure allows accurate budgeting for your entire weight management journey. The psychological benefit of knowing exact costs reduces financial stress during treatment, whilst avoiding surprise charges that might force treatment interruption due to unexpected expenses.
Start Your Weight Management Journey: Wegovy Ordering and Support
Ready to begin with Wegovy following our transparent dosage chart pricing? Visit https://everydaymeds.co.uk/collections/wegovy to complete your clinical assessment and review our complete range of single pens and bundle options. New customers receive £40 off with code FIRST40, whilst returning customers save with code DOSE25—these discounts apply at checkout to reach our published prices. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment suits your individual circumstances and preferences. Our clinical team provides ongoing support throughout your dose escalation and maintenance phases, ensuring optimal results from your chosen prescription-only medicine. Remember that both treatments work best alongside a reduced-calorie diet and increased physical activity, with regular medical monitoring ensuring safe and effective progress.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
